Skip to main content
Alligator Bioscience logo

Alligator Bioscience — Investor Relations & Filings

Ticker · ATORX ISIN · SE0024173637 LEI · 549300E15VI0MB7LXV19 ST Manufacturing
Open in API
Filings indexed 612 across all filing types
Latest filing 2021-02-26 Interim / Quarterly Rep…
Country SE Sweden
Listing ST ATORX

About Alligator Bioscience

https://alligatorbioscience.se/en/

Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for the period 'January-December 2020', containing detailed financial statements (Net sales, Operating profit/loss, Cash flow, Equity), performance measures, and management commentary on business operations and clinical development. It is clearly a year-end financial report for a period shorter than a full annual report (as it focuses on the 2020 fiscal year results in a summary format typical of a year-end report or fourth-quarter report), fitting the definition of an Interim/Quarterly Report (IR). FY 2020
2021-02-26 English
Alligator Bioscience AB: Last day of trading in paid subscription shares (Sw. BTA)
Share Issue/Capital Change Classification · 1% confidence The document is a press release dated February 23, 2021, announcing the last day of trading for paid subscription shares (BTA) following a rights issue that raised approximately SEK 86m. It details the registration of the rights issue with the Swedish Companies Registration Office and provides key dates (last day of trading, stop day). This content directly relates to a capital raising/financing activity and subsequent administrative steps related to share structure changes. This fits best under the 'Capital/Financing Update' category (CAP), as it is an announcement detailing the conclusion and administrative finalization of a rights issue, which is a form of capital raising.
2021-02-23 English
Alligator Bioscience AB: Sista dag för handel med BTA
Report Publication Announcement Classification · 1% confidence The document is a press release dated February 23, 2021, concerning the final trading day for 'BTA' (betald tecknad aktie - paid subscribed share) following a rights issue that raised approximately 86 MSEK. The core subject is the conclusion of a capital-raising activity (rights issue) and the subsequent administrative steps (BTA trading cessation, registration with the Swedish Companies Registration Office). This directly relates to changes in the company's capital structure and financing activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it pertains to a specific corporate finance event.
2021-02-23 Swedish
Alligator Biosciences företrädesemission övertecknad
Share Issue/Capital Change Classification · 1% confidence The document is a press release dated January 27, 2021, titled "Alligator Biosciences företrädesemission övertecknad" (Alligator Bioscience's rights issue oversubscribed). It details the outcome of a rights issue (nyemission med företrädesrätt), including the amount raised (approx. 86 MSEK), the subscription rate (163%), the resulting increase in shares and share capital, and the timeline for BTA conversion. This content directly relates to the company's fundraising and capital structure changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple announcement of a report publication (RPA), as it contains the substantive results of the financing event itself.
2021-01-27 Swedish
Alligator Bioscience’s rights issue oversubscribed
Share Issue/Capital Change Classification · 1% confidence The document is a press release dated January 27, 2021, announcing the successful completion and oversubscription of a 'Rights Issue' (a type of share issue where existing shareholders have pre-emptive rights). The text details the number of shares subscribed for, the capital raised (approximately SEK 86 million), the purpose (funding clinical studies), and the resulting increase in share capital and dilution. This activity directly relates to changes in the company's capital structure and the issuance of new shares to existing shareholders via a pre-emptive offering. This aligns precisely with the definition for 'Share Issue/Capital Change' (SHA). It is not a general earnings release (ER), a full annual report (10-K), or a general regulatory filing (RNS), as it concerns a specific capital market transaction.
2021-01-27 English
Larger shareholder and board member transfer subscription rights free of charge to qualified investors
Capital/Financing Update Classification · 1% confidence The document is a press release dated January 21, 2021, announcing actions related to a previously authorized Rights Issue (a capital raising activity). Specifically, it details the transfer of subscription rights by major shareholders and a board member to qualified investors who have committed to subscribing for shares. This activity directly concerns the company's capital structure and fundraising efforts. The document explicitly mentions the Rights Issue and the transfer of subscription rights, which falls under the scope of financing activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP). It is not the full prospectus or the final results of the vote, but an announcement detailing a key step in the capital raise process.
2021-01-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.